Related Experiment Video
Updated: Sep 25, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Coverage for pertussis vaccination during pregnancy with 4 models of vaccine delivery: a quasiexperimental,
Yinan Li1, Nicholas Brousseau1, Maryse Guay1
1Department of Epidemiology, Biostatistics & Occupational Health (Li), McGill University; CHU Sainte-Justine Research Center (Li, Laghdir, Boucoiran, Tapiéro), Montréal, Que.; Direction des risques biologiques et de la santé au travail (Brousseau, Dubé), Institut national de la santé publique du Québec; CHU de Quebec Research Center (Brousseau, Dubé), Université Laval, Québec City, Que.; Research Center (Guay), Hôpital Charles-Lemoyne, Longueuil, Que.; Département des sciences de la santé communautaire (Guay), Université de Sherbrooke, Sherbrooke, Que.; Department of Obstetrics & Gynecology (Boucoiran), School of Public Health, Université de Montréal; Infectious Diseases Division (Tapiéro), Department of Pediatrics, CHU Sainte-Justine; Department of Microbiology, Infectious Diseases and Immunology (Quach), Université de Montréal; Infection Prevention and Control (Quach), Clinical Department of Laboratory Medicine, CHU Sainte-Justine, Montréal, Que.
Background:
Vaccination of pregnant people with a vaccine containing acellular pertussis (tetanus-diphtheria-acellular pertussis [Tdap]) has been recommended in Canada since 2018, and the evaluation of delivery models for efficient maternal Tdap administration is a priority for the Quebec Ministry of Health. We implemented 3 vaccine delivery models, in addition to the existing standard of practice model, and compared the vaccine coverage achieved by the 4 models in Quebec.
Methods:
In this quasiexperimental, multicentre observational study, we recruited pregnant people at less than 21 weeks' gestation in 4 Quebec regions from April to October 2019. We compared 4 vaccine delivery models: local community service centres (centre local de services communautaires [CLSCs], baseline), family medicine groups (FMGs), obstetrics clinic and the oral glucose challenge test (OGCT). In addition to the CLSCs, 3 FMGs, 1 obstetric clinic and a hospital-based OGCT screening program participated. We determined vaccination status from a self-reported questionnaire, the Quebec Immunization Registry or medical charts. We compared model-specific (for participants recruited to a model and subsequently vaccinated within that model) and overall vaccine coverage (considering all vaccine delivery pathways) and used logistic regression to adjust for sociodemographic variables.
Results:
Overall, 946 of 1000 recruited pregnant people were eligible for analyses. Vaccination via the FMGs achieved the highest model-specific vaccine coverage (67.8%, 95% confidence interval [CI] 60.5%-74.4%), but coverage was not significantly different from the CLSCs (63.8%, 95% CI 57.6%-69.6%). For overall vaccine coverage, the FMG (86.5%, 95% CI 80.6%-90.9%) and obstetrics models (85.9%, 95% CI 80.9%-89.7%) achieved significantly higher vaccine coverage than the CLSCs (66.3%, 95% CI 60.1%-71.9%). The OGCT model did not improve overall vaccine coverage (61.8%, 95% CI 56.1%-67.2%).
Interpretation:
Compared with CLSCs, overall vaccine coverage was higher when Tdap was offered in FMGs or an obstetrics clinic providing prenatal care. Health professionals involved in pregnancy follow-up recommending and offering the vaccine may be a key factor in optimizing vaccine coverage.
More Related Videos
13:00Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits Oryctolagus cuniculus
Published on: July 31, 2021
09:09Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring
Published on: August 17, 2022
Related Concept Videos
Vaccinations
Intrauterine Drug Delivery Systems
Development of the Oral Microbiota
Vaccines
Respiratory Syncytial Virus Disease